Showing results (681-690 of 3,470) with videos related to

Sort By:
Pageof 347
Clinical Pharmacokinetics|March 15, 2017
Scientific Rationale for Determining the Bioequivalence of Inhaled DrugsOmar S Usmani, Mathieu Molimard, Vaibhav Gaur, et al.
Clinical Pharmacokinetics|February 26, 2017
Clinical Pharmacokinetics of ParitaprevirRajeev M Menon, Akshanth R Polepally, Amit Khatri, et al.
Clinical Pharmacokinetics|March 12, 2019
Population Pharmacokinetic Modeling of Benralizumab in Adult and Adolescent Patients with AsthmaLi Yan, Bing Wang, Yen Lin Chia, et al.
Clinical Pharmacokinetics|February 16, 2017
Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy SubjectsPatrick C Dolder, Yasmin Schmid, Andrea E Steuer, et al.
Clinical Pharmacokinetics|March 17, 2019
Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal ImpairmentChristian Rolfo, Judith de Vos-Geelen, Nicolas Isambert, et al.
Clinical Pharmacokinetics|July 27, 2019
Physiologically Based Pharmacokinetic Modeling to Characterize Acetaminophen Pharmacokinetics and N-Acetyl-p-Benzoquinone Imine (NAPQI) Formation in Non-Pregnant and Pregnant WomenPaola Mian, John N van den Anker, Kristel van Calsteren, et al.
Clinical Pharmacokinetics|July 24, 2019
Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic MalignanciesKen Ogasawara, Kathryn Newhall, Stephen E Maxwell, et al.
Clinical Pharmacokinetics|February 4, 2017
Successful Use of [14C]Paracetamol Microdosing to Elucidate Developmental Changes in Drug MetabolismMiriam G Mooij, Esther van Duijn, Catherijne A J Knibbe, et al.
Clinical Pharmacokinetics|November 24, 2018
Pharmacokinetic and Pharmacodynamic Modeling to Optimize the Dose of Vestronidase Alfa, an Enzyme Replacement Therapy for Treatment of Patients with Mucopolysaccharidosis Type VII: Results from Three TrialsYulan Qi, Kathleen McKeever, Julie Taylor, et al.
Clinical Pharmacokinetics|April 21, 2017
Comparison of a Novel Formulation of Abiraterone Acetate vs. the Originator Formulation in Healthy Male Subjects: Two Randomized, Open-Label, Crossover StudiesRonald Goldwater, Azra Hussaini, Bill Bosch, et al.
Pageof 347